HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results